Sarepta Therapeutics, Inc.

Symbol: SRPT

NASDAQ

132.3

USD

Market price today

  • 735.9300

    P/E Ratio

  • -304.4910

    PEG Ratio

  • 12.51B

    MRK Cap

  • 0.00%

    DIV Yield

Sarepta Therapeutics, Inc. (SRPT) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.88%

Operating Profit Margin

-0.07%

Net Profit Margin

0.01%

Return on Assets

0.01%

Return on Equity

0.02%

Return on Capital Employed

-0.04%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Douglas S. Ingram Esq.
Full-time employees:1314
City:Cambridge
Address:215 First Street
IPO:1997-06-04
CIK:0000873303

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.882% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.068%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.012%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.005% return, is a testament to Sarepta Therapeutics, Inc.'s adeptness in optimizing resource deployment. Sarepta Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.020%. Furthermore, the proficiency of Sarepta Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.036% return on capital employed.

Stock Prices

Sarepta Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $131.61, while its low point bottomed out at $127. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Sarepta Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing SRPT liquidity ratios reveals its financial health of the firm. The current ratio of 404.93% gauges short-term asset coverage for liabilities. The quick ratio (297.37%) assesses immediate liquidity, while the cash ratio (70.20%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio404.93%
Quick Ratio297.37%
Cash Ratio70.20%

Profitability Ratios

SRPT profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 2.43% underscores its earnings before tax deductions. The effective tax rate stands at 50.39%, revealing its tax efficiency. The net income per EBT, 49.61%, and the EBT per EBIT, -35.92%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -6.76%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin2.43%
Effective Tax Rate50.39%
Net Income per EBT49.61%
EBT per EBIT-35.92%
EBIT per Revenue-6.76%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.05, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 334.61% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding297
Days of Inventory Outstanding822
Operating Cycle930.97
Days of Payables Outstanding201
Cash Conversion Cycle730
Receivables Turnover3.35
Payables Turnover1.81
Inventory Turnover0.44
Fixed Asset Turnover3.74
Asset Turnover0.44

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -5.68, and free cash flow per share, -6.96, depict cash generation on a per-share basis. The cash per share value, 14.80, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.38, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-5.68
Free Cash Flow per Share-6.96
Cash per Share14.80
Operating Cash Flow Sales Ratio-0.38
Free Cash Flow to Operating Cash Flow Ratio1.23
Cash Flow Coverage Ratio-0.43
Short Term Coverage Ratio-5.05
Capital Expenditure Coverage Ratio-4.44
Dividend Paid and Capex Coverage Ratio-4.44

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 38.43%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.29, we discern the balance between debt and equity financing. The long-term debt to capitalization, 54.12%, and total debt to capitalization, 56.32%, ratios shed light on its capital structure. An interest coverage of 43.96 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio38.43%
Debt Equity Ratio1.29
Long Term Debt to Capitalization54.12%
Total Debt to Capitalization56.32%
Interest Coverage43.96
Cash Flow to Debt Ratio-0.43
Company Equity Multiplier3.35

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 13.46, provides a glimpse into top-line earnings distributed across each share. Net income per share, -5.80, reflects the portion of profit attributed to each share. The book value per share, 9.30, represents the net asset value distributed per share, while the tangible book value per share, 8.98, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share13.46
Net Income Per Share-5.80
Book Value Per Share9.30
Tangible Book Value Per Share8.98
Shareholders Equity Per Share9.30
Interest Debt Per Share13.83
Capex Per Share-0.95

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 33.26%, indicates top-line expansion, while the gross profit growth, 37.83%, reveals profitability trends. EBIT growth, 50.05%, and operating income growth, 50.05%, offer insights into operational profitability progression. The net income growth, 23.81%, showcases bottom-line expansion, and the EPS growth, 27.77%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth33.26%
Gross Profit Growth37.83%
EBIT Growth50.05%
Operating Income Growth50.05%
Net Income Growth23.81%
EPS Growth27.77%
EPS Diluted Growth27.77%
Weighted Average Shares Growth5.53%
Weighted Average Shares Diluted Growth5.53%
Operating Cash Flow Growth-53.99%
Free Cash Flow Growth-65.18%
10-Year Revenue Growth per Share3101.76%
5-Year Revenue Growth per Share196.14%
3-Year Revenue Growth per Share94.22%
10-Year Operating CF Growth per Share-183.55%
5-Year Operating CF Growth per Share7.58%
3-Year Operating CF Growth per Share-493.32%
10-Year Net Income Growth per Share-75.25%
5-Year Net Income Growth per Share-6.18%
3-Year Net Income Growth per Share18.39%
10-Year Shareholders Equity Growth per Share27.29%
5-Year Shareholders Equity Growth per Share-40.31%
3-Year Shareholders Equity Growth per Share-4.82%
Receivables Growth69.32%
Inventory Growth58.29%
Asset Growth4.35%
Book Value per Share Growth111.54%
Debt Growth-13.64%
R&D Expense Growth0.03%
SGA Expenses Growth6.75%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 9,878,317,140, captures the company's total value, considering both debt and equity. Income quality, 0.93, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.39, gauges operational efficiency, while the research and development to revenue, 70.57%, highlights investment in innovation. The ratio of intangibles to total assets, 0.91%, indicates the value of non-physical assets, and capex to operating cash flow, 17.43%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value9,878,317,140
Income Quality0.93
Sales General and Administrative to Revenue0.39
Research and Development to Revenue70.57%
Intangibles to Total Assets0.91%
Capex to Operating Cash Flow17.43%
Capex to Revenue-7.03%
Capex to Depreciation-148.31%
Stock-Based Compensation to Revenue14.68%
Graham Number34.84
Return on Tangible Assets-16.57%
Graham Net Net-2.57
Working Capital1,925,672,000
Tangible Asset Value829,717,000
Net Current Asset Value174,092,000
Invested Capital1
Average Receivables349,701,500
Average Payables130,396,500
Average Inventory263,413,500
Days Sales Outstanding129
Days Payables Outstanding400
Days of Inventory On Hand784
ROIC-13.05%
ROE-0.62%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 12.94, and the price to book ratio, 12.94, reflect the market's valuation relative to the company's book value. The price to sales ratio, 8.91, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -19.12, and price to operating cash flows, -23.30, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio12.94
Price to Book Ratio12.94
Price to Sales Ratio8.91
Price Cash Flow Ratio-23.30
Price Earnings to Growth Ratio-304.49
Enterprise Value Multiple-218.45
Price Fair Value12.94
Price to Operating Cash Flow Ratio-23.30
Price to Free Cash Flows Ratio-19.12
Price to Tangible Book Ratio10.37
Enterprise Value to Sales7.95
Enterprise Value Over EBITDA-36.88
EV to Operating Cash Flow-19.72
Earnings Yield-6.02%
Free Cash Flow Yield-6.60%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sarepta Therapeutics, Inc. (SRPT) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 735.930 in 2024.

What is the ticker symbol of Sarepta Therapeutics, Inc. stock?

The ticker symbol of Sarepta Therapeutics, Inc. stock is SRPT.

What is company IPO date?

IPO date of Sarepta Therapeutics, Inc. is 1997-06-04.

What is company current share price?

Current share price is 132.300 USD.

What is stock market cap today?

The market cap of stock today is 12505498740.000.

What is PEG ratio in 2024?

The current -304.491 is -304.491 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1314.